SARM1 Inhibitors Market SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)

SARM1 Inhibitors Market Size - Analysis

The SARM1 Inhibitors Market is estimated to be valued at USD 5 Mn in 2024 and is expected to reach USD 727 Mn by 2031, growing at a compound annual growth rate (CAGR) of 103.7% from 2024 to 2031.

SARM1 Inhibitors Market Trends

Investment in neurological research has been increasing steadily over the past few years. There has been a growing acknowledgement of the impacts of neurodegenerative diseases on public health and economies. Several funding agencies and foundations have increased their budgets towards finding treatments for conditions such as Alzheimer's, Parkinson's, and ALS. Research into the mechanisms underlying axon degeneration has received significant support. One promising new area is SARM1 inhibition.

 Neurodegenerative conditions like Alzheimer's and Parkinson's are increasing at an alarming rate as the population ages globally. It is estimated that over 50 million people are living with dementia worldwide currently and the numbers are projected to triple in the coming decades. Even in countries with improved healthcare systems and life expectancy, the prevalence of these diseases keeps rising unabated. The personal and societal burden of neurodegeneration is enormous and will continue growing unless effective treatment options become available.

Market Challenge - The high cost and complexity of drug development for neurodegenerative disorders may limit market growth

 Recent years have seen major advances in the understanding of genetic contributions and molecular pathways involved in neurodegenerative disorders. This has enabled the application of precision or personalized medicine approaches targeting specific patient subpopulations. For example, identifying biomarkers that stratify patients based on disease subtypes or progression stages allows clearer evaluation of drug efficacy. Advances are also being made in developing therapies tailored to genetic mutations associated with familial forms of diseases. These personalized strategies hold promise to more effectively treat subsets of patients. Additionally, emerging technologies like computer modeling of brain networks offer potential to better predict drug effects and optimize dosing regimens. Such precision approaches aim to maximize benefits and minimize side effects for patients. If successful, they could justify higher drug prices and promote further investment. Overall, ongoing progress in stratifying these complex diseases offers significant growth potential for molecularly targeted SARM1 inhibitor therapies.

Prescribers preferences of SARM1 Inhibitors Market

The treatment of neurodegenerative diseases typically follows a stepwise approach based on disease progression and severity of symptoms. For mild cases of Alzheimer's disease, prescribers commonly start with cholinesterase inhibitor medications such as donepezil (Aricept). These drugs work to boost acetylcholine levels in the brain and provide cognitive benefits.

For late-stage Alzheimer's and severe dementia, non-pharmacologic approaches become important. At this point, medications provide little cognitive benefit but may help manage behaviors like aggression, anxiety and insomnia. Antipsychotics like quetiapine (Seroquel) are often used off-label for their sedating effects.

Treatment Option Analysis of SARM1 Inhibitors Market

Lung cancer is typically classified into four main stages—I, II, III, and IV—depending on the size and spread of the primary tumor and whether it has metastasized to lymph nodes or distant organs. Treatment options vary significantly depending on the stage.

For stage IV metastatic NSCLC, platinum-doublet chemotherapy remains a first-line option. However, immunotherapy with PD-1 inhibitors like pembrolizumab, nivolumab or atezolizumab have become increasingly prominent first-line treatments due to superior efficacy and reduced side effects compared to chemotherapy. For patients with EGFR or ALK mutations, targeted therapies like gefitinib, erlotinib or alectinib are preferred.

Key winning strategies adopted by key players of SARM1 Inhibitors Market

Collaboration and partnerships have been a major winning strategy for companies in this space. In 2021, Cleave Therapeutics entered a collaboration with Eli Lilly to develop and commercialize SARM1 inhibitors for degenerative diseases. This gave Cleave access to Lilly's significant R&D and commercialization capabilities while reducing development costs.

Focusing on neurodegenerative diseases has paid off as they represent large patient populations and reimbursement is often favorable. Disorders like ALS, MS and spinal cord injury have few approved treatment options, so SARM1 inhibitors could see rapid adoption. Cleave and Astrocyte are specifically developing therapies for ALS and spinal cord injury based on this strategy.

Licensing approved technologies accelerated development timelines. In 2019, Astellas licensed the rights to ASP-7037 from Astrocite, enabling it to leverage preclinical work already completed on the compound and advance it into clinical trials more rapidly versus internal discovery. This allowed Astellas to establish an early-mover advantage in the clinic versus internal pipeline programs.

Segmental Analysis of SARM1 Inhibitors Market

 Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, sub-segment contributes the highest share of 45.7% in the SARM1 inhibitors market owing to significant unmet medical needs. ALS is a fatal neurodegenerative disease with limited treatment options and high mortality rates. Currently, there is no cure for ALS and the only FDA approved drug, Riluzole, provides modest benefits. This clearly indicates a high unmet need for more effective therapies.

Insights, By Type of Molecule: Advantages over biologics drive small molecules demand

Targeting SARM1, a protein localized in axons and neuronal cell bodies, requires inhibitors with excellent CNS penetration ability. Most ALS patients also have significant neuromuscular denervation which necessitates inhibitors that can effectively reach degenerating motor neurons and neuromuscular junctions. Small molecules, due to their optimal physicochemical properties, are better equipped than biologics to overcome the blood-brain-barrier and reach subcellular sites of SARM1 action. These critical pharmacokinetic advantages make small molecule SARM1 inhibitors highly desirable for developing effective ALS therapies.

Additional Insights of SARM1 Inhibitors Market

• The SARM1 inhibitors market is poised for exponential growth, driven by rising investment in research, particularly in North America. The increasing prevalence of neurodegenerative diseases such as ALS and MS, coupled with advancements in precision medicine, positions SARM1 inhibitors as a promising therapeutic frontier. The market’s rapid expansion is also fueled by ongoing preclinical studies and the growing involvement of both academic institutions and biotech companies.
• Washington University has been at the forefront, receiving 64% of grants for SARM1 research, highlighting its key role in market innovation.

Competitive overview of SARM1 Inhibitors Market

The major players operating in the SARM1 inhibitors market include Disarm Therapeutics, Nura Bio, Washington University, Asha Therapeutics and UCB Pharma.

Recent Developments in SARM1 Inhibitors Market

SARM1 Inhibitors Market Segmentation

• By Indication
  • Amyotrophic Lateral Sclerosis (ALS)
  • Multiple Sclerosis (MS)
  • Peripheral Neuropathies
  • Glaucoma
• By Type of Molecule
  • Small Molecules
  • Biologics